The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Name of the ingredient
Poliglusam derived from Aspergillus niger (AAN)
Synonym: Chitosan derived from Aspergillus niger
Definition of the ingredient
Poliglusam (2-Amino-2-deoxy-poly-D-glucosamine) is an insoluble, non-digestible fibre preparation derived from the cell walls of non-genetically modified Aspergillus niger mycelium. Poliglusam derived from Aspergillus niger contains not more than 15% beta-glucan.
Molecular formula: (C6H11NO4)n, (C6H10O5)n
| Test | Method reference | Acceptance criteria |
|---|---|---|
| Description | ||
| Appearance | Visual | Fine free-flowing powder |
| Colour | Visual | Off-white to slightly brownish |
| Odour | Organoleptic | Odourless |
| Characteristics | ||
| Loss on drying | Ph Eur 2.2.32 | Not more than 10 % w/w |
| Viscosity 1% in acetic acid 1% | Ph Eur 2.2.10 | 2.5-15 mPa.s |
| Degree of acetylation | Ph Eur 2.2.20 | 0 to 30 mol% |
| Tapped density | Ph Eur 2.9.34 | 0.7-1.0 g/cm3 |
| Identification | ||
| Chitosan | Fourier Transform Infrared Spectrum (Ph Eur 2.2.24) | Matches spectrum of authenticated Ph Eur Reference standard |
| Assay | ||
| Chitosan | Content determined by calculation | Not less than 80% w/w |
| Glucan | Ph Eur 2.2.25 | Not more than 15% w/w |
| Test | Method reference | Acceptance criteria |
|---|---|---|
| Incidental metals and non-metals | ||
| While ingredient manufacturers are encouraged to include limits for Incidental metals and non-metals, it is the product into which those substances are formulated that contains the ingredient, alone or in combination with other ingredients, must comply with the acceptance criteria set in the United States Pharmacopeia - National Formulary (USP-NF) general chapter ' Elemental Contaminants in Dietary Supplements'. When testing is performed at the raw material stage, calculation of the total daily exposure in the finished product should be performed. This calculation is based on the quantity of each ingredient present in the product, the maximum potential contamination given the proposed limits for each raw material and the daily dose of the product. | ||
| Other organic or inorganic impurities or toxins | ||
| Ash | Ph Eur 2.4.16 | Not more than 3 % w/w |
| Protein | Derivatisation and reaction with ninhydrin prior to analysis according to Ph Eur 2.2.25 | Not more than 2 % w/w |
| Aflatoxin B1 | Samples are extracted in an acetonitrile/water mixture, and the filtered extract is purified on an imunoaffinity column and then analysed by LC/MS/MS. [1][2] | Not more than 0.5 µg.kg-1 |
| Aflatoxin B2 | Not more than 0.5 µg.kg-1 | |
| Aflatoxin G1 | Not more than 0.5 µg.kg-1 | |
| Aflatoxin G2 | Not more than 1 µg.kg-1 | |
| Ochratoxin A | Not more than 1 µg.kg-1 | |
| Fumonisin B1 | Samples are extracted by a methanol/water/acetonitrile mixture and the filtered extract is purified on an immunoaffinity column. Analysis is then conducted using LC/MS/MS against 13C- internal standards. [3] | Not more than 1 µg.kg-1 |
| Fumonisin B2 | Not more than 100 µg.kg-1 | |
| Microbiology | ||
| While substance manufacturers are encouraged to include limits for objectionable microorganisms, it is the product into which those substances are formulated that is subject to a legally binding set of criteria. The Therapeutic Goods Order No. 77 'Microbiological Standards for Medicines' - external site mandates that any finished product that contains the ingredient, alone or in combination with other ingredients, must comply with the microbial acceptance criteria set by Clause 9 of the Order. | ||
| Notes | ||
|
||
Key to abbreviations
HPLC = High-pressure liquid chromatography
LC/MS/MS = Liquid Chromatography-Tandem Mass Spectrometry
Ph Eur = European Pharmacopoeia